

The 52nd Annual Meeting of the Japanese Society of Toxicology To Participants

Notice of changes to the Program & Abstract Book

We would like to inform you that the following changes have been made after printing the Program & Abstract Book.

Lunchtime Seminar L1-7		
Applicable page	10, 162	
Before the change		After the change
Sponsored by : Axcelead Drug Discovery Partners, Inc. / Future Peak, Inc.		⇒ Sponsored by : Axcelead Drug Discovery Partners, Inc. / Mediford Corporation

Workshop 2		
Applicable page	60-61, S72	
Before the change		After the change
W2-1 Izuru MIYAWAKI 9:15-9:21 W2-2 Naoko TANAKA 9:21-9:42 W2-3 Takafumi YOTSUMOTO 9:42-10:03 W2-4 Takeshi WATANABE 10:03-10:24 W2-5 Sho AKAI 10:24-10:45		⇒ W2-1 Izuru MIYAWAKI 9:15-9:23 W2-2 Naoko TANAKA 9:23-9:51 W2-3 Takafumi YOTSUMOTO 9:51-10:14 W2-4 Takeshi WATANABE 10:14-10:37 Plenary Q&A 10:37-10:45

Candidates for the Excellent Presentation Award(Oral•Poster) P-126E		
Applicable page	77, 105, S153	
Before the change		After the change
P-126E Application of Drug-Induced Liver Injury (DILI) Prediction Model Using Integrated Datasets and Machine Learning Approaches ○Taro KAKUZAKI Research Division, Chugai Pharmaceutical, Co., Ltd.		⇒ Withdrawal
Applicable page	11, 77	
<Session time> Before the change		After the change
Candidates for the Excellent Presentation Award (Oral) 4 15:04 - 15:58		⇒ 15:04 - 15:52 *The individual presentation times for P-128E to P-139E have been moved forward by one abstract.

Poster Session P-288		
Applicable page	128, S218	
Before the change		After the change
P-288 An exploratory toxicity study focusing on the metabolite ○Sanae OMI Eisai Co., Ltd.		⇒ Withdrawal

Lunchtime Seminar L3-5		
Applicable page	165	
Before the change		After the change
Targeted Protein Degradation of the Androgen Receptor by ARCC-4 and ARD-2128: Proteomic and Therapeutic Potential in AR-driven Cancers		⇒ ①Targeted Protein Degradation of the Androgen Receptor by ARCC-4 and ARD-2128: Proteomic and Therapeutic Potential in AR-driven Cancers Speaker: Chun-Yao Lee, Ph.D.(Managing Director, Eurofins Panlabs Discovery Services Taiwan) ②Evaluation of Drugs in Assays to Address Neuroinflammation, Cytotoxicity, Safety, and Broader Biological Effects Speaker: Alastair J. King, Ph.D (Head of Biology, Eurofins Discovery)

Poster Session P-237		
Applicable page	S198	
Before the change		After the change
P-237 Subacute exposure of 2, 2', 4, 4' -tetrabromodiphenyl ether induced liver injury by inhibiting mitochondrial autophagy and increasing NLRP3 inflammasome in mice ○Shuhua XI China Medical University, School of Public Health		⇒ Withdrawal